EGFR and cancer: As well, combination of MAbs with TKIs, e.g., trastuzumab plus anti-EGFR/anti-ErbB2 such as lapatinib or pertuzumab, revealed of clinical benefit for recurrent cancers following trastuzumab treatment for instance (Geyer et al., 2006; Joensuu et al., 2006).